Defining the Next Era of Cancer Therapeutics

Building on the momentum of AACR 2026, WuXi AppTec was honored to host an outstanding group of regional industry leaders and experts at our Spring Science Forum in Cambridge to discuss the latest advances shaping oncology R&D.

During the forum, highlights of our most recent oncology contributions were presented via our AACR 2026 posters, covering topics including protein degraders, antibody-drug conjugates, bispecific antibodies, and tumor resistance mechanisms.

Missed the forum or want to revisit the science? We’re pleased to now make all posters available for download.

Forum Posters: Defining the Next Era of Cancer Therapeutics:

PD-1 Blockade with a DLL3 TCE Potentiates Efficacy in SCLC: Download HERE
Novel E3 Ligase to Support Targeted Protein Degradation: Download HERE
Mechanistic Profiling of ADC-resistant Cancer Cell Lines: Download HERE
Unveiling Mechanisms of MRTX1133 Resistance: Download HERE
Development of the Venetoclax-Resistant AML Model: Download HERE
From tLNP Screening to Functional Validation_Efficacy of CAR-T Delivery: Download HERE
Synthetic-Lethality Screening with PARP inhibition and Non-CRBN Degrader ID through HTS and Target Deconvolution by Proximity Labeling: Download HERE
EpCAM-CD3 Bispecific Antibody-Encoding mRNA Delivered by lung-targeted lipid nanoparticles suppresses orthotopic lung tumor growth: Download HERE
An Integrated In Vitro Profiling Platform for the Simultaneous Assessment of Anti-Cancer Efficacy and Multi-Organ Toxicity: Download HERE
Synchronously implanted cold tumor abrogates anti-PD-1 response of hot tumor in a syngeneic mouse model: Download HERE
Development of a High-Throughput Assay Platform for the Screening of Selective Integrin Inhibitors in Cancer: Download HERE
Therapeutic Potential of BTK-targeted Degrader in B-Cell Malignancies Harboring Ibrutinib-Resistant Mutation: Download HERE
Integrated ADC platform from discovery to functional evaluation: Download HERE